Year-over-year, this metric grew by 100.0%, from -$276.00M to $0.00. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests poor asset valuation or declining market demand for non-core business units, while a decrease indicates stable asset values or successful divestiture execution.
This represents non-cash charges recognized when the carrying value of long-lived assets held for sale exceeds their fai...
Common in large pharmaceutical companies undergoing portfolio restructuring or M&A integration.
operating_impairment_of_long_lived_assets_to_be_disposed_of| Q3 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $571.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $485.00M | $246.00M | $115.00M | $268.00M | -$276.00M | -$699.00M | -$99.00M | $0.00 | $0.00 |
| QoQ Change | — | -100.0% | — | — | — | — | — | — | -49.3% | -53.3% | +133.0% | -203.0% | -153.3% | +85.8% | +100.0% | — |
| YoY Change | — | -100.0% | — | — | — | — | — | — | — | — | — | -156.9% | -384.1% | -186.1% | -100.0% | +100.0% |